

NATA Accredits ColoSTAT® Clinical Testing Service

- ✓ The National Association of Testing Authorities (NATA) — Australia’s independent peak laboratory accreditation body — has confirmed that ColoSTAT® satisfies all applicable technical and quality requirements under ISO 15189:2022, providing independent third-party accreditation of the clinical suitability of the Company’s blood-based colorectal cancer testing service for its intended use. As part of this assessment, the test’s validation and intended clinical application were reviewed in accordance with the National Pathology Accreditation Advisory Council (NPAAC) requirements for laboratory-developed tests.
- ✓ ColoSTAT® is now formally listed within the accredited scope of Rhythm’s ISO 15189:2022-certified laboratory in Parkville, Victoria, enabling Rhythm to offer ColoSTAT® as an accredited clinical diagnostic testing service to referring clinicians and patients across Australia.
- ✓ Accreditation provides clinicians and patients with independent, authoritative assurance that ColoSTAT® meets the highest internationally recognised standards for analytical quality, laboratory competence, and result traceability in medical testing.
- ✓ NATA accreditation represents a key regulatory milestone enabling the commercial launch of ColoSTAT® testing services in Australia and is an important prerequisite for potential Medicare Benefits Schedule (MBS) listing discussions, strengthening Rhythm’s reimbursement pathway in Australia.

Melbourne, Australia, 9th March 2026: Rhythm Biosciences Ltd (‘RHY’, the ‘Company’ or the ‘Group’) (ASX: RHY), a transformative, predictive cancer diagnostics technology company is pleased to advise that the National Association of Testing Authorities (NATA) has confirmed successful completion of the variation-to-scope assessment for the Company’s ColoSTAT® blood-based colorectal cancer test. Following this assessment, ColoSTAT® is now included within the accredited scope of Rhythm’s ISO 15189:2022 laboratory in Parkville, Victoria.

Directors

This milestone formally recognises ColoSTAT® as an accredited clinical laboratory service, confirming that the laboratory and test method meet internationally recognised standards for quality, competence, and traceability under the ISO 15189:2022 standard. NATA accreditation reflects the independent assurance that Rhythm’s laboratory systems and the technical performance of ColoSTAT® meet the globally recognised clinical laboratory standard. The inclusion of ColoSTAT® as an accredited clinical service enables Rhythm to commence offering the test to referring clinicians and patients in Australia as part of the Company’s commercial launch strategy.

Rhythm intends to progressively expand clinician awareness and referral pathways as part of the rollout of ColoSTAT® testing services in the Australian market. NATA accreditation represents an important prerequisite for engagement with the Medical Services Advisory Committee (MSAC) regarding a potential Medicare Benefits Schedule (MBS) listing. MBS reimbursement, if achieved, would support broader clinical adoption of ColoSTAT® within Australia’s healthcare system.

Management Comment

Dr David Atkins, Managing Director and CEO of Rhythm Biosciences, commented: “Today’s announcement completes a two-stage accreditation journey. When we received ISO 15189:2022 accreditation for our Parkville laboratory in November 2025, that recognised the quality and competence of our facility. Today, NATA has independently accredited ColoSTAT® within our laboratory scope — confirming that the assay meets the internationally recognised standards for medical testing quality and technical performance. Together, these represent the most rigorous form of independent validation available for a clinical diagnostic service in Australia. This is not just a regulatory checkbox — it is a strong, independent confirmation of the science and the technical competence of our laboratory team that gives clinicians and patients real confidence in the test. We believe accreditation will support physician referral conversations and accelerate our pathway to broader adoption and reimbursement.”

Next Steps

The Company will provide further updates as it progresses the commercial rollout of ColoSTAT®.

- ENDS -

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via investors@rhythmbio.com.

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer, and saving lives. Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions. The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and X.

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer can be curable. The ColoSTAT® Test is Rhythm Bioscience's simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. It is intended for individuals with symptoms associated with Colorectal Cancer (CRC). The ColoSTAT® Test is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

About geneType™

geneType™ is a sophisticated genetic risk assessment testing platform that combines clinical, family history and genetic data to provide comprehensive risk assessments for various diseases. The platform leverages polygenic risk scores and clinical risk factors to generate personalized health insights, helping individuals and healthcare providers make more informed medical decisions. The technology allows for risk assessment across multiple conditions including breast cancer, cardiovascular disease, diabetes, colorectal cancer, prostate cancer, and melanoma. The tests are delivered through healthcare providers and genetic counsellors, ensuring appropriate clinical oversight and support for patients receiving their results. The platform's multi-disease assessment capabilities and clinical utility position it well to capture growing demand in the preventative healthcare and precision medicine markets. For more information, please visit www.genetype.com.